Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for...

Related Keywords

Shanghai ,China ,United States ,Zhejiang ,Shanxi ,Fujian ,Shenzhen ,Guangdong ,Anhui ,Beijing ,Liaoning ,Hunan ,Jiangsu ,Guizhou ,Hubei ,Sichuan ,Gansu ,Yong Liu ,Brii Bio ,Rogers Luo ,Sinopharm Holding Co Ltd ,Therapeutics Beijing Co Ltd ,Party Committee Of Sinopharm Holding ,National Health Commission Of China ,Us National Institutes Of Health ,Drug Administration ,Brii Biosciences Limited Bio ,Sinopharm Holding ,National Healthcare Security Administration Of China ,National Medical Products Administration ,Tsinghua University ,Brii Biosciences Limited ,National Health Commission ,Treatment Guidelines ,Pilot Edition ,General Manager ,Greater China ,Chief Executive Officer ,Deputy Secretary ,Party Committee ,National Healthcare Security Administration ,Healthcare Security Administrations ,Health Commissions ,Delta Plus ,Biosciences Limited ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Infection Control ,Biotechnology ,